“Repotrectinib: a promising new therapy for advanced non-small cell lung cancer”
Тип публикации: Journal Article
Дата публикации: 2024-11-05
WOS Q2
БС2
SJR: 0.387
CiteScore: —
Impact factor: 1.6
ISSN: 20490801
PubMed ID:
39649881
Краткое описание
Nonsmall cell lung cancer (NSCLC) is the major cause of cancer-related mortality worldwide, accounting for 84% of lung cancer cases. The newly FDA-approved kinase inhibitor, repotrectinib (AUGTYRO), offers a promising option for treating advanced or metastatic NTRK/ROS1-positive Nonsmall cell lung cancer. Repotrectinib has demonstrated significant efficacy in clinical trials. Notably, the phase 1/2 TRIDENT-1 study showed impressive progression-free survival and intracranial activity in both TKI-naïve and pretreated patients. With its high response rates and manageable side effects, repotrectinib is set to play a significant role in treating ROS1+ and NTRK+advanced solid tumors, highlighting the ongoing need for research and clinical application.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Для доступа к списку цитирований публикации необходимо авторизоваться.
Топ-30
Журналы
|
1
|
|
|
European Journal of Medicinal Chemistry
1 публикация, 14.29%
|
|
|
HemaSphere
1 публикация, 14.29%
|
|
|
Journal of Translational Medicine
1 публикация, 14.29%
|
|
|
Journal of Receptor and Signal Transduction Research
1 публикация, 14.29%
|
|
|
Frontiers in Oncology
1 публикация, 14.29%
|
|
|
Results in Chemistry
1 публикация, 14.29%
|
|
|
Russian Chemical Reviews
1 публикация, 14.29%
|
|
|
1
|
Издатели
|
1
2
|
|
|
Elsevier
2 публикации, 28.57%
|
|
|
Wiley
1 публикация, 14.29%
|
|
|
Springer Nature
1 публикация, 14.29%
|
|
|
Taylor & Francis
1 публикация, 14.29%
|
|
|
Frontiers Media S.A.
1 публикация, 14.29%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 публикация, 14.29%
|
|
|
1
2
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.
Вы ученый?
Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Войти с ORCID
Метрики
7
Всего цитирований:
7
Цитирований c 2025:
7
(100%)
Цитировать
ГОСТ |
RIS |
BibTex |
MLA
Цитировать
ГОСТ
Скопировать
Rais T. et al. “Repotrectinib: a promising new therapy for advanced non-small cell lung cancer” // Annals of Medicine and Surgery. 2024. Vol. 86. No. 12. pp. 7265-7269.
ГОСТ со всеми авторами (до 50)
Скопировать
Rais T., Shakeel A., Naseem L., Nasser N., Aamir M. “Repotrectinib: a promising new therapy for advanced non-small cell lung cancer” // Annals of Medicine and Surgery. 2024. Vol. 86. No. 12. pp. 7265-7269.
Цитировать
RIS
Скопировать
TY - JOUR
DO - 10.1097/ms9.0000000000002717
UR - https://journals.lww.com/10.1097/MS9.0000000000002717
TI - “Repotrectinib: a promising new therapy for advanced non-small cell lung cancer”
T2 - Annals of Medicine and Surgery
AU - Rais, Taruba
AU - Shakeel, Amna
AU - Naseem, Laiba
AU - Nasser, Nathalie
AU - Aamir, Minahil
PY - 2024
DA - 2024/11/05
PB - Ovid Technologies (Wolters Kluwer Health)
SP - 7265-7269
IS - 12
VL - 86
PMID - 39649881
SN - 2049-0801
ER -
Цитировать
BibTex (до 50 авторов)
Скопировать
@article{2024_Rais,
author = {Taruba Rais and Amna Shakeel and Laiba Naseem and Nathalie Nasser and Minahil Aamir},
title = {“Repotrectinib: a promising new therapy for advanced non-small cell lung cancer”},
journal = {Annals of Medicine and Surgery},
year = {2024},
volume = {86},
publisher = {Ovid Technologies (Wolters Kluwer Health)},
month = {nov},
url = {https://journals.lww.com/10.1097/MS9.0000000000002717},
number = {12},
pages = {7265--7269},
doi = {10.1097/ms9.0000000000002717}
}
Цитировать
MLA
Скопировать
Rais, Taruba, et al. ““Repotrectinib: a promising new therapy for advanced non-small cell lung cancer”.” Annals of Medicine and Surgery, vol. 86, no. 12, Nov. 2024, pp. 7265-7269. https://journals.lww.com/10.1097/MS9.0000000000002717.
Ошибка в публикации?